{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-030193","form_type":"8-K","ticker":"OTLC","cik":"0000908259","company_name":"Oncotelic Therapeutics, Inc.","filed_at":"2021-12-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:16.168481+00:00","generated_at":"2026-06-28T04:42:59.736026+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Oncotelic issues $0.5M in convertible notes at $0.07/share to repay existing debt","bullets":["Issued two convertible notes: $0.25M to Talos Victory Fund and $0.25M to Mast Hill Fund.","Notes carry 12% annual interest, mature in one year, convertible at $0.07 per share.","Proceeds used to fully repay May 2021 Geneva Note ($203,750) and June 2021 Geneva Note ($103,750).","Financing round aims for up to $1.0M; first two tranches total $0.5M.","JH Darbie & Co. entitled to 10% cash finder's fee and 10% warrant coverage."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-030193","json":"https://secwatch.observer/filing/0001493152-21-030193.json","markdown":"https://secwatch.observer/filing/0001493152-21-030193.md","text":"https://secwatch.observer/filing/0001493152-21-030193.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/908259/000149315221030193/0001493152-21-030193-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908259/000149315221030193/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T04:42:59.736026+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}